8-K: Vivani Medical Announces Positive Preclinical Data and Secures Funding for Weight Management Programs

Vivani Medical reports successful initial administration and full enrollment in the LIBERATE-1 study, positive preclinical data for NPM-139, and secures $8.25M in equity financing.

Summary

• Vivani Medical, Inc. reported its fourth quarter and full year 2024 financial results and provided a business update.
• The company is developing miniaturized, ultra long-acting drug implants for chronic weight management.
• Key achievements include successful initial administration and full enrollment in the LIBERATE-1 study of NPM-115 (exenatide implant).
• Positive preclinical data was reported for NPM-139 (semaglutide implant), showing weight loss comparable to semaglutide injections.
• Vivani secured $8.25 million in equity financing, extending its financial runway into the second quarter of 2026.
• The company is advancing both the NPM-115 and NPM-139 programs, targeting once or twice-yearly dosing.
• Vivani is also planning to spin off Cortigent, Inc. as an independent publicly traded company.
• As of December 31, 2024, Vivani had $19.7 million in cash, cash equivalents, and restricted cash.
• The net loss for the full year 2024 was $23.5 million, compared to $25.7 million in 2023.
• Research and development expenses for the year were $15.7 million, a decrease from $17.0 million in the previous year.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with successful clinical trial progress, promising preclinical data, and secured funding. The company is making strides in a high-growth market with a differentiated technology.

Positives

• Successful initial administration and full enrollment in the LIBERATE-1 study indicates strong progress in the NPM-115 program.
• Positive preclinical data for NPM-139 suggests potential for a highly effective once-yearly weight management treatment.
• The $8.25 million equity financing provides financial stability and supports the development of key programs.
• The planned spin-off of Cortigent allows Vivani to focus on its core biopharmaceutical business.
• The NanoPortal platform offers a differentiated approach to drug delivery, potentially improving patient adherence and outcomes.
• The company's cash position of $19.7 million provides a solid foundation for ongoing operations.
• The decrease in net loss from $25.7 million to $23.5 million year-over-year indicates improved financial management.

Negatives

• The company reported a net loss of $23.5 million for the full year 2024.
• Research and development expenses decreased, potentially indicating a slowdown in certain areas of development.
• General and administrative expenses increased during the fourth quarter of 2024, driven by professional services and stock-based compensation.

Risks

• The development of NPM-115 and NPM-139 is subject to regulatory approvals and clinical trial risks.
• The company's ability to access additional capital is crucial for funding its ongoing operations and development programs.
• Competition from other companies in the GLP-1 market could impact the commercial success of Vivani's products.
• The spin-off of Cortigent is subject to regulatory and listing requirements.
• The company's reliance on third parties for manufacturing, research, and testing poses potential risks to its supply chain and development timelines.
• The company's forward looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivanis control.

Future Outlook

Vivani anticipates announcing key milestones associated with the LIBERATE-1 trial in mid-2025 and further announcements regarding the advancement of the NPM-139 program, including projected timelines for filing an Investigational New Drug Application and pending regulatory clearance, initiation of an initial clinical trial.

Management Comments

• Adam Mendelsohn, Ph.D., Vivanis Chief Executive Officer, stated that the company transitioned to a clinical-stage biotechnology company and achieved significant milestones in both the NPM-115 and NPM-139 programs.
• Dr. Mendelsohn added that the LIBERATE-1 study is progressing as planned and the company remains on track for top-line data in mid-2025.
• Dr. Mendelsohn noted that the company raised funding to support operations into the second quarter of 2026.

Industry Context

Vivani Medical is operating in the rapidly growing GLP-1 market, targeting chronic weight management and type 2 diabetes. The company's long-acting implant technology aims to address the issue of medication non-adherence, a significant challenge in these therapeutic areas. The company estimates that the GLP-1 market will reach $130B in sales by 2030.

Comparison to Industry Standards

• The company's NPM-139 preclinical data showed weight loss comparable to semaglutide injections (Ozempic/Wegovy), indicating potential competitiveness with established GLP-1 therapies.
• Vivani's NanoPortal implant technology is designed to address the release-rate variability issues that led to the FDA's non-approval of Intarcia's ITCA 650.
• The company estimates that the GLP-1 market will reach $130B in sales by 2030.
• The company's implants are designed to be smaller and use a smaller gauge needle than Intarcia's ITCA-650.

Stakeholder Impact

• Shareholders: The positive developments and secured funding are likely to be viewed favorably by shareholders.
• Employees: The company's growth and advancement of its programs provide opportunities for employees.
• Patients: The development of long-acting implants could improve medication adherence and outcomes for patients with obesity and type 2 diabetes.
• Investors: The company's progress and financial stability may attract further investment.

Next Steps

• Announcement of key milestones associated with the LIBERATE-1 trial in mid-2025.
• Further announcements regarding the advancement of the NPM-139 program.
• Filing a Form 10 registration statement with the SEC to enable the spin-off of Cortigent.

Key Dates

Keywords

Vivani Medical, NPM-115, NPM-139, GLP-1, Obesity, Weight Management, Semaglutide, Exenatide, Implants, NanoPortal, Cortigent, Clinical Trials, Financing